Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (November 2025)
29 slides from Can-fite Biopharma's investor presentation, November 2025
Slide 1: Small Molecules for Big Clinical Needs
Small Molecules for Big Clinical Needs TM November 2025 https://www.canfite.com/ NYSE American:CANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in th
Slide 3: Company Overview
Safe Drugs for the Treatment of 1 Oncological and Inflammatory Diseases Advanced Clinical Stage Pipeline; 2 Short Regulatory Approval Pathway Company (FDA & EMA) Overview 3 Successful Out-licensing Deals Financial Summary (Ticker: CANF) Listed on NYSE American and Tel-Aviv Stock Exchange 4 ~26.2 M A
Slide 4: Unique Platform Technology
Unique Platform Technology Specific oral therapy aimed at diseased cells Therapeutic Target Pathological PathologicalCells Cell A3 Adenosine Receptor (A3AR) • Global leader in discovering and developing drugs that target the A3 adenosine receptor (A3AR) Pipeline Drugs • Small molecule, orally bioava
Slide 5: Pipeline Drugs
Pipeline Drugs Drug/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Piclidenoson Psoriasis Pivotal Phase III agreed with FDA & EMA; Ongoing Lowe syndrome Phase II to be initiated Pets Osteoarthritis Positive Phase II data; Out licensed to Vetbiolix Namodenoson Liver Cancer Pivotal Phase III agreed w
Slide 6: Corporate Partnerships: Current Out-Licensing Deals
CorporatePartnerships: Corporate Partnerships:Current CurrentOut-Licensing Out-LicensingDeals Deals Psoriasis, Liver Cancer, MASH Eastern Europe Pancreatic cancer received in upfront and milestone $20M payments Spain, Switzerland, Austria Psoriasis potential based on regulatory China, Taiwan, Hong K
Slide 7: Piclidenoson Drug Candidate
Piclidenoson Drug Candidate Chemical Properties • Nucleoside derivative • Highly Selective A3AR Agonist • Molecular weight - 510.29 • Water insoluble • Half lifetime in blood – 8-9 hours Piclidenoson Inflammatory Indications 7
Slide 8: Piclidenoson: Moderate to Severe Psoriasis
Piclidenoson Moderate to Severe Psoriasis 8
Slide 9: Piclidenoson - Drug Profile for Treatment of Plaque Psoriasis
Piclidenoson for the Treatment Piclidenoson - Drug Profile of Plaque Psoriasis Rationale for Development • Overexpression of the A3AR target in Keratinocytes of psoriasis patients • Robust anti-inflammatory effect manifested by specific apoptosis of inflammatory cells • Piclidenoson inhibits IL-17 &
Slide 10: Phase III Study Endpoints - Achieved
Phase III Study Endpoints - Achieved I Study Design Primary Endpoint PASI 75 Significant Superiority of Piclidenoson 3 mg vs. Placebo 10 Secondary Endpoint Subjects Achieving PGA2 for Piclidenoson vs Placebo NYSE American: CANF Excellent Safety Profile 10
Slide 11: Pivotal Phase III – Currently Enrolling
Pivotal Phase III – Currently Enrolling II • Pivotal Phase III study that has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) • Oral piclidenoson 3 mg twice daily (BID) in subjects with moderate-to-severe plaque psoriasis, compared with place
Slide 12: Topical Piclidenoson Treatment Inhibits Psoriasis in Imiquimod-induced Model
Topical Piclidenoson Treatment Inhibits Psoriasis in an Topical Piclidenoson Treatment Inhibits Psoriasis in Imiqimod-induced Model Imiqimod-induced Model Vehicle 8 Vehicle 7 CF 101 6 PASI SCORE ** 5 * 4 Piclidenoson 3 DAY 6 DAY7 DAY8 Psoriasis Area and Severity Index (PASI): cumulative score ,eryth
Slide 13: Piclidenoson: Lowe Syndrome
Piclidenoson Lowe Syndrome 13
Slide 14: Lowe Syndrome: A Rare Genetic Disease
Lowe Syndrome: A Rare Genetic Disease • Lowe Syndrome, known as oculo-cerebro- renal syndrome (OCRL), an X-linked genetic condition occurring in males • OCRL gene is mutated, located on the X chromosome • Prevalence is approximately 1 in 500,000 and a market of $100M in the U.S. • Rare genetic disea
Slide 15: Phase II Study - to be Initiated
Phase II Study - to be Initiated • Piclidenoson was found by a Naples University Researcher (Dr. Antonnela De Matteis ) to resolve the manifestations of Lowe Syndrome including a marked improvement in kidney, brain and ophtalmic functions • An agreement for co-development has been signed between Can
Slide 16: Piclidenoson: Pets Osteoarthritis
Piclidenoson Pets Osteoarthritis Partnership with Veterinarian Company Vetbiolix 16
Slide 17: Pets Osteoarthritis Piclidenoson - Drug Profile
Pets Osteoarthritis Piclidenoson - Drug Profile • The canine osteoarthritis market is projected to reach $3 billion by 2028 • Vetbiolix exercised the option to enter into a full in license agreement with Can-Fite for companion animals including dogs and cats • Projected Income of $325M1 to Can-Fite
Slide 18: Namodenoson Drug Candidate
Namodenoson Drug Candidate Chemical Properties • MW: 544.73 g/mol • Water Insoluble • Half life: 12 hours • Nucleoside Derivative Namodenoson • Orally Bioavailable • High Stability in the Liver Oncology & MASH (NASH) 18
Slide 19: Namodenoson: Advanced Liver Cancer
Namodenoson Advanced Liver Cancer 19
Slide 20: Advanced Liver Cancer
Advanced Liver Cancer Piclidenoson - Drug Profile Rationale for Development • A3AR is over-expressed in human hepatocellular carcinoma (HCC) cells. • Namodenoson, induces de- regulation of the Wnt and NF- kB signalling pathways resulting in apoptosis of HCC cells. IL-23 & IL-17 • In Phase II study i
Slide 21: HCC Phase II Study – Recent Data
HCC Phase II Study – Recent Data Complete disappearance of tumor lesions Presented at the AASLD 2022 & ASCO- Breakthrough 2023 Meeting Complete Response in a Namodenoson Treated Patient • Patient was enrolled in Phase II liver cancer study • Continued treatment with Namodenoson for >9 years under Op
Slide 22: Liver Cancer
Liver Cancer • FDA and EMA agreed on Pivotal Phase 3 study protocol Pivotal Phase III • Interim analysis to be conducted by Independent Data Currently Enrolling Monitoring Committee (IDMC) after 50% of planned 450 Orphan Drug Designation patients are enrolled and treated with FDA&EMA • Namodenoson e
Slide 23: Namodenoson: Pancreatic Cancer
Namodenoson Pancreatic Cancer 23
Slide 24: Pancreatic Cancer
Pancreatic Cancer Piclidenoson - Drug Profile Rationale for Development • Namodenoson induces 90% growth inhibition of pancreatic cancer cells • The molecular mechanism of action includes de-regulation of the Wnt and the Ras signaling pathways • In vivo studies showed robust inhibition of pancreatic
Slide 25: Pancreatic Cancer Exploratory Phase IIa Study
Pancreatic Exploratory Phase IIa Study Cancer Second line therapy • Open label Currently Enrolling: 50% Enrollment Achieved • Oral dose of Namodenoson: 25 mg twice daily • Primary End point: Safety • Secondary Endpoints: Objective response, progression-free survival, duration of response, disease co
Slide 26: Namodenoson: MASH
Namodenoson MASH 26
Slide 27: MASH - Metabolic Associated Steatohepatitis
MASH - Metabolic Piclidenoson - DrugAssociated Profile Steatohepatitis Rationale for Development: Liver protective Effect • Induction of anti - inflammatory effect manifested by reduction of NAFLD Activity Score (NAS) • Anti-fibrotic effect • Anti-steatotic effect: significant decrease in steatosis,
Slide 28: MASH (NASH) Phase IIa and IIb Studies
Phase IIa Study Successfully Concluded: MASH (NASH) • Reduced liver fat content (LFC) • Anti-Inflammatory effect • Dose selection for Phase IIb determined Addressing Severe Unmet Need • Decrease in body weight • Excellent safety profile Currently Enrolling Patients for Phase IIb Study a Phase IIb St
Slide 29: Closing Highlights
Closing Highlights Oral drugs with proven safety and efficacy in Pivotal Phase III studies Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer; Namodenoson is also in Phase II for MASH and pancreatic cancer Monetizing advanced portfolio through corporate partnerships – Pi
Can-Fite BioPharma — Investor Presentation (November 2025) on 6ix